Our investment banker is pushing us to use the Guideline Transaction Method to price our company, but we have invested heavily in proprietary automation that makes our gross margins twice the industry average. How do we leverage the Income Approach under the IVS 105 framework to force the buyer to value our future cash flows instead of applying a generic industry multiplier to our current EBITDA?

Question

Tyler Smith · Accepted Answer

Relying solely on the Guideline Transaction Method often penalizes high-performing companies because it lump-sums you with average competitors that do not possess your operational efficiencies. Under the IVS 105 valuation framework, you have the right to argue that the Income Approach is a far more appropriate method because your proprietary automation directly drives superior, durable future cash flows. To force this shift in the valuation methodology, you must present a highly structured, data-driven financial model. Start by showing how your automated workflows lower your cost of goods sold and reduce your customer acquisition costs compared to industry benchmarks. This is where your EOS data becomes invaluable. Pull the historical tracking metrics from your Weekly Meetings and show how your operational Rocks have systematically eliminated manual labor and human error, leading to double the average profit margins. Under IVS 105, you can argue that the principle of substitution fails if there are no truly comparable automated businesses in your local market. By presenting a detailed Discounted Cash Flow model that projects these high-margin cash flows, supported by years of consistent operational data, you make it mathematically impossible for the buyer to justify a generic, low-multiple valuation. This forces them to price your company based on the actual economic value your systems generate.